5-Aza-2′-deoxycytidine Restores Proapoptotic Function of p53 in Cancer Cells Resistant to p53-induced Apoptosis

REFERENCES

• Vogelstein B., Lane D., Levine A. J. Surfing the p53 network. Nature 2000; 408(6810)307–310
   PubMed Web of Science ®Google Scholar
• Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10(4)431–442
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004; 432(7015)307–315
   PubMed Web of Science ®Google Scholar
• Green D. R., Evan G. I. A matter of life and death. Cancer Cell 2002; 1(1)19–30
   PubMed Web of Science ®Google Scholar
• Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434(7035)864–870
   PubMed Web of Science ®Google Scholar
• Gorgoulis V. G., Vassiliou L. V., Karakaidos P., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434(7035)907–913
   PubMed Web of Science ®Google Scholar
• Oda E., Ohki R., Murasawa H., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288(5468)1053–1058
   PubMed Web of Science ®Google Scholar
• Yu J., Zhang L., Hwang P. M., et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7(3)673–682
   PubMed Web of Science ®Google Scholar
• Nakano K., Vousden K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7(3)683–694
   PubMed Web of Science ®Google Scholar
• Oda K., Arakawa H., Tanaka T., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102(6)849–862
   PubMed Web of Science ®Google Scholar
• Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell 2000; 100(1)57–70
   PubMed Web of Science ®Google Scholar
• Jones P. A., Baylin S. B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3(6)415–428
   PubMed Web of Science ®Google Scholar
• Feinberg A. P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4(2)143–153
   PubMed Web of Science ®Google Scholar
• Baylin S. B. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; S4–11, 2 Suppl 1
   Google Scholar
• Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16(1)6–21
   PubMed Web of Science ®Google Scholar
• Johnstone R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1(4)287–299
   PubMed Web of Science ®Google Scholar
• Egger G., Liang G., Aparicio A., et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429(6990)457–463
   PubMed Web of Science ®Google Scholar
• Lyko F., Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005; 97(20)1498–1506
   PubMed Web of Science ®Google Scholar
• Soussi T., Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1(3)233–240
   PubMed Web of Science ®Google Scholar
• Chim C. S., Wong A. S., Kwong Y. L. Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias. Am J Hematol 2005; 80(4)282–287
   PubMed Web of Science ®Google Scholar
• Lodygin D., Diebold J., Hermeking H. Prostate cancer is characterized by epigenetic silencing of 14–3-3sigma expression. Oncogene 2004; 23(56)9034–9041
   PubMed Web of Science ®Google Scholar
• Oshiro M. M., Futscher B. W., Lisberg A., et al. Epigenetic regulation of the cell type-specific gene 14–3-3sigma. Neoplasia 2005; 7(9)799–808
   PubMed Web of Science ®Google Scholar
• Polyak K., Waldman T., He T. C., et al. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996; 10(15)1945–1952
   PubMed Web of Science ®Google Scholar
• Noda A., Ning Y., Venable S. F., et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211(1)90–98
   PubMed Web of Science ®Google Scholar
• Sato M., Suemori H., Hata N., et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000; 13(4)539–548
   PubMed Web of Science ®Google Scholar
• Hida S., Ogasawara K., Sato K., et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000; 13(5)643–655
   PubMed Web of Science ®Google Scholar
• Whang Y. E., Wu X., Suzuki H., et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95(9)5246–5250
   PubMed Web of Science ®Google Scholar
• Ishida S., Yamashita T., Nakaya U., et al. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn J Cancer Res 2000; 91(2)174–180
   PubMedGoogle Scholar
• Yamano S., Tokino T., Yasuda M., et al. Induction of transformation and p53-dependent apoptosis by adenovirus type 5 E4orf6/7 cDNA. J Virol 1999; 73(12)10095–10103
   PubMed Web of Science ®Google Scholar
• Watson J. V., Chambers S. H., Smith P. J. A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry 1987; 8(1)1–8
   PubMedGoogle Scholar
• Sgonc R., Gruber J. Apoptosis detection: an overview. Exp Gerontol 1998; 33(6)525–533
   PubMed Web of Science ®Google Scholar
• Danial N. N., Korsmeyer S. J. Cell death: critical control points. Cell 2004; 116(2)205–219
   PubMed Web of Science ®Google Scholar
• Shibue T., Takeda K., Oda E., et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 2003; 17(18)2233–2238
   PubMed Web of Science ®Google Scholar
• Villunger A., Michalak E. M., Coultas L., et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302(5647)1036–1038
   PubMed Web of Science ®Google Scholar
• Jeffers J. R., Parganas E., Lee Y., et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4(4)321–328
   PubMed Web of Science ®Google Scholar
• Miyashita T., Reed J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80(2)293–299
   PubMed Web of Science ®Google Scholar
• Polyak K., Xia Y., Zweier J. L., et al. A model for p53-induced apoptosis. Nature 1997; 389(6648)300–305
   PubMed Web of Science ®Google Scholar
• Huang J., Perez-Burgos L., Placek B. J., et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006; 444(7119)629–632
   PubMed Web of Science ®Google Scholar
• Le Cam L., Linares L. K., Paul C., et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006; 127(4)775–788
   PubMed Web of Science ®Google Scholar
• Nakajima W., Tanaka N. Synergistic induction of apoptosis by p53-inducible Bcl-2 family proteins Noxa and Puma. J Nippon Med Sch 2007; 74(2)148–157
   PubMedGoogle Scholar
• McCurrach M. E., Connor T. M., Knudson C. M., et al. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997; 94(6)2345–2349
   PubMed Web of Science ®Google Scholar
• Matzke M., Aufsatz W., Kanno T., et al. Genetic analysis of RNA-mediated transcriptional gene silencing. Biochim Biophys Acta 2004; 1677(1–3)129–141
   PubMed Web of Science ®Google Scholar